Evaluation of the immunological response of patients with childhood
cancer treated with the personalized peptide vaccine for refractory soft
tissue sarcoma: An early phase II study
We evaluated the peptide-specific immunoglobulin G (IgG) response and
the safety of the personalized peptide vaccine in four children with
refractory solid cancer. Although the pre-vaccination IgG responses were
suppressed compared to those observed in children with upper respiratory
tract infection, IgG levels against the vaccinated peptides after 12
times vaccination increased in all the three cases tested.
Vaccination-related adverse effects were grade 1 injection-site local
skin lesions. One patient had maintained remission for 37 months. The
remaining three patients exhibited progressive disease. These results
indicate the next steps in phase II studies considering their immune
boosting effect and safety.